)
Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.
Sanket Koul is a mass communication graduate with a PG diploma in English Journalism from IIMC Delhi. As a correspondent at Business Standard, he covers the pulse of the social sector, from industry and institutional developments, to the government's latest moves in education, healthcare, pharmaceuticals and medical devices sectors.
Stricter rules to curb antimicrobial resistance may limit antibiotic sales growth in 2026, as India tightens OTC use and pushes prescription-led, responsible consumption
In a gazette notification dated January 23, the Union health ministry proposed adding a new clause under Rule 95 of the Drugs Rules, 1945
Syngene trims FY26 revenue guidance by up to 5% as inventory correction for veterinary drug Librela hits profits, even as core research and CDMO business grows
Developer says Q3 sales dropped due to Dahlias pause, no new launches
Realty major states gross zero debt on high net cash position
Move comes just months before nivolumab patent expiry in India on May 2, 2026
Ahead of Budget 2026, realtors seek higher home loan tax deductions, a wider affordable housing definition, and dispute-resolution reforms to revive housing demand
CDSCO has flagged seven drug batches as spurious and listed 167 others as not of standard quality in its December 2025 surveillance, covering common medicines for BP, pain and allergies
The health ministry has amended the NDCT Rules to cut approval timelines for new drug trials and testing by half, aiming to speed up innovation while easing regulatory processes for most applications
Dr Reddy's Laboratories reported a sharp fall in December-quarter profit as declining Lenalidomide sales in the US weighed on earnings, even as India revenues and branded businesses remained resilient
Elan Group awards an Rs 840 crore construction contract to Tata Projects for its ultra-luxury residential project 'Elan-The Statement' in Sector 49, Gurugram
Units priced ₹1 crore and above increase market share to 63% of total units sold in 2025
JB Pharma reports a 22% rise in Q3 FY26 profit as strong growth in domestic and international formulations offsets flat CDMO revenues
With ₹86,588 crore in projects cleared in 2025, Gurugram cements its place as India's hottest real estate hub-spanning premium homes, IT parks and mass housing
Revised criteria for reserved categories; doctor bodies criticise the move
Elie Saab to open first retail store this year
Demand slowdown, buyers getting priced out of affordable housing, reflecting in FY26 numbers
Centre deployed a national outbreak response team and activated emergency protocols after two suspected Nipah virus cases were detected in West Bengal
The report added that operating margins are expected to remain steady at 27 to 28 per cent as these institutions will incur higher staff salaries and other related costs
Bhumika Realty raises ₹170 crore from Aditya Birla Sun Life AMC-BGO credit platform to fund its ₹700-crore mixed-use project in Faridabad